NASDAQ: PODD
$246.61 −4.89 (−1.94%)
As of Feb 27, 2026 · 4:00 PM ET

Insulet Corporation isn’t just another medtech name — it’s the company behind Omnipod, the sleek, tubeless insulin delivery system that has quietly been winning the automated insulin delivery (AID) race. If diabetes tech were Formula 1, Insulet would be racing a carbon-fiber pod with Bluetooth.

The question for investors in 2026 isn’t whether Insulet is a terrific business.

It is.

The question is whether you’re buying a Ferrari… at Ferrari pricing.

Let’s break down the 7 triggers driving PODD right now — and whether this is a growth feast or a valuation hangover.

🚨 Trigger #1: Insider Confidence (The $1M Signal)

When stocks dip, you watch insiders.

And here?

They’re buying.

• CEO Ashley McEvoy purchased ~$1.03M worth of stock (+45% stake increase).

• Director Michael Minogue added nearly $500K.

• Another director bought near $311 earlier.

These weren’t stock grants. These were open-market purchases around $240–$250.

Translation: the captain is not abandoning ship — she’s adding cargo.

That’s a strong psychological floor.

🏦 Trigger #2: Institutions Own… Everything

Institutional ownership: 103% of float.

Yes, that’s mathematically weird. It typically reflects lending, shorting mechanics, and reporting overlaps. But the takeaway is simple:

Wall Street’s biggest names are in this stock:

• Vanguard (owns 12.36% of shares outstanding)

• BlackRock (9.35%)

• FMR (8.99%)

• Capital Research

• State Street

This is a core medtech holding, not a speculative flyer.

Big funds don’t park billions unless they believe the moat is real.

🔍 For Insulet (PODD)'s Institutional Ownership breakdown, see here. 

🩺 Trigger #3: Shorts? What Shorts?

Short interest: 2.16%

Days to cover: 1.33

In other words: almost nobody is betting aggressively against Insulet.

This isn’t a squeeze story. It’s a conviction story.

📈 Trigger #4: Analysts Love It

Consensus: Buy / Strong Buy
Average 12-month price target: $354–$379
High target: $435

That implies ~40%+ upside from current levels.

Analysts cite:

• Omnipod 5 dominance

• Type 2 diabetes expansion

• International growth

• Recurring consumables model

The bullish case isn’t subtle.

🧬 Trigger #5: 30% Off Highs

ATH (Nov 2025): $354.88
Current: ~$246

That’s a ~30% correction.

For a stock compounding revenue at 30% annually, that’s not trivial.

But is it a bargain?

Not so fast.

💸 Trigger #6: Valuation — Ouch

Let’s talk numbers.

• Trailing P/E: ~71x

• Forward P/E: ~40x

• PEG: ~1.74

• Price/Sales: 6.5x

• Price/Book: 11.4x

• EV/EBITDA: ~36x

You are absolutely paying for quality.

Gross margins north of 71%.
Revenue growth at 31%.
Operating income rising.

But 70x earnings means:

The market expects near-perfection.

If growth slips even slightly, compression hits fast.

This is not a “deep value” story.

It’s a premium growth compounder.

🏆 Trigger #7: The Earnings Machine

Q4 2025 Revenue: $783.8M (+31%)
Full Year 2025 Revenue: $2.7B (+31%)

10th consecutive year of 20%+ growth.

International revenue up 50% in Q4.
600,000+ active users globally.
FDA algorithm upgrades.
$350M buyback authorization.

And they’re guiding:

• 20–22% growth for 2026

• 25% adjusted EPS growth

• Margin expansion

That’s not a stumble.

That’s controlled acceleration.

👉 Want the full picture? Dive into Insulet (PODD)'s financials here.

🧠 The Real Growth Engine: Type 2 Expansion

This is the big one.

Type 1 diabetes is stable and established.

Type 2? Massive.

Insulet saw 100% YoY growth in Type 2 new customer starts.

That is where the multi-year runway lives.

If Omnipod becomes a standard in Type 2 insulin-dependent patients?

This story compounds for years.

⚠️ The Risks

Let’s be honest.

• Single-product dependence (Omnipod)

• Heavy competition (Dexcom, Tandem, Medtronic)

• Manufacturing concentration

• 70x earnings multiple

• Market-wide valuation risk

If we enter a broad bear market, high-multiple growth names may get hit first.

PODD is not immune.

💡💡💡 Curious about another deep oil exploration play?
Check our take on UnitedHealth Group.

🎯 The FUNanc1al Verdict

PODD is a 5-star steakhouse.

The service is elite.
The chef is consistent.
The reviews are glowing.

But the bill is expensive.

At $200?

Compelling.

At $246?

Reasonable — but not cheap.

At $300+?

You’re paying full prestige pricing.

✅ Quick Take / TL;DR

• Insiders buying aggressively
• Institutions fully committed
• Revenue compounding at 30%
• Type 2 expansion = major runway
• 70x earnings = premium valuation
• Not a short squeeze story
• High-quality growth — but priced for excellence

❓ FAQ

Is Insulet profitable?
Yes. Strong operating margins and growing EPS.

Why is institutional ownership above 100%?
Share lending mechanics and reporting overlaps.

What’s the biggest risk?
Valuation compression if growth slows.

Is this a buy now?
For long-term growth investors — potentially.
For value investors — maybe wait closer to $200.

🧩 Food for Thought: The Cross-Hub Connection

This isn’t just a finance story.

It’s a Health + Tech + Demographics story.

Aging populations.
Rising Type 2 prevalence.
Digital health integration.

This is where biotech meets SaaS-like recurring revenue.

In FUNanc1al terms?

It’s a Health Hub + Stocks Hub compounder.

👤 About the Author

Frédéric Marsanne is the founder of FUNanc1al — part market analyst, part storyteller, part accidental comedian. A longtime investor, entrepreneur, and venture-builder across tech, biotech, and fintech, he now blends sharp insights with a twist of humor to help readers laugh, learn, live better lives, and invest a little wiser. When not decoding insider buys or poking fun at earnings calls, he’s building Cl1Q, writing fiction, painting, or discovering new passions to FUNalize.

🧾⚠️📢 Fun(anc1al) but Serious Disclaimer: 🧾⚠️📢

This is not investment advice. It’s Smart + Fun perspective. Investing in equities — especially high-growth, high-multiple stocks — involves risk, including total loss of capital. Always do your own research, know your risk tolerance, and consult a licensed financial professional if you must. 

Past performance is not indicative of future results. Resist FOMO and never invest money you can’t afford to lose. 

We laugh, we analyze, we meme.
We’re FUNanc1al — not financial advisors. 😄📉📈

Invest at your own risk. 🎢📉 
Love at any pace. Laugh at every turn. 😄
Be Happy. 😄😄

🧭 Looking for a Different Angle?

• 🕵️ Insider Purchases Center
• 📣 Follow the Pundits Hub
• 📈 Young Guns & Turnaround Stocks — Track More Growth (and Growing-Pain) Plays
• 😆 Stock Market Humor & Serious-ish Plays
• 🌍 See the world differently and check out more international market picks and fun takes. Explore International Investment Opportunities and value plays 💸 Cheap Stocks with (Maybe) Big Upside

😂 Laugh, Learn, Invest: funanc1al.com | Funanc1al: Where Even Finance Meets Funny